Showing results (381-390 of 405) with videos related to

Sort By:
Pageof 41
Science Advances|June 1, 2022
Light-activated molecular machines are fast-acting broad-spectrum antibacterials that target the membraneAna L Santos, Dongdong Liu, Anna K Reed, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoJaneta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Global Change Biology|February 12, 2021
Heatwave-induced synchrony within forage fish portfolio disrupts energy flow to top pelagic predatorsMayumi L Arimitsu, John F Piatt, Scott Hatch, et al.
Journal of Medicinal Chemistry|February 9, 2026
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of CancerJames Neef, Kimberly S Straley, Chinmoy Mukherjee, et al.
Molecular Ecology Resources|March 25, 2011
Sperm whale population structure in the eastern and central North Pacific inferred by the use of single-nucleotide polymorphisms, microsatellites and mitochondrial DNASarah L Mesnick, Barbara L Taylor, Frederick I Archer, et al.
The Journal of Experimental Biology|August 19, 2025
The key to bubble-net feeding: how humpback whale morphology functionally differs from other baleen whalesCameron Nemeth, William T Gough, Paolo S Segre, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2015
Mutant IDH is sufficient to initiate enchondromatosis in miceMakoto Hirata, Masato Sasaki, Rob A Cairns, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Pageof 41